Cargando…

Pan-Pim Kinase Inhibitor AZD1208 Suppresses Tumor Growth and Synergistically Interacts with Akt Inhibition in Gastric Cancer Cells

PURPOSE: Pim kinases are highly conserved serine/threonine kinases, and different expression patterns of each isoform (Pim-1, Pim-2, and Pim-3) have been observed in various types of human cancers, including gastric cancer. AZD1208 is a potent and selective inhibitor that affects all three isoforms...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Miso, Lee, Kyung-Hun, Min, Ahrum, Kim, Jeongeun, Kim, Seongyeong, Jang, Hyemin, Lim, Jee Min, Kim, So Hyeon, Ha, Dong-Hyeon, Jeong, Won Jae, Suh, Koung Jin, Yang, Yae-Won, Kim, Tae Yong, Oh, Do-Youn, Bang, Yung-Jue, Im, Seock-Ah
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Cancer Association 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6473293/ https://www.ncbi.nlm.nih.gov/pubmed/29879757 http://dx.doi.org/10.4143/crt.2017.341

Ejemplares similares

Loss of PIM2 enhances the anti-proliferative effect of the pan-PIM kinase inhibitor AZD1208 in non-Hodgkin lymphomas
por: Kreuz, S., et al.
Publicado: (2015)

AZD1208, a pan‐Pim kinase inhibitor, inhibits adipogenesis and induces lipolysis in 3T3‐L1 adipocytes
por: Park, Yu‐Kyoung, et al.
Publicado: (2018)

Antitumor effect of a WEE1 inhibitor and potentiation of olaparib sensitivity by DNA damage response modulation in triple-negative breast cancer
por: Ha, Dong-Hyeon, et al.
Publicado: (2020)

The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression
por: Harada, Masako, et al.
Publicado: (2015)

Homologous repair deficiency score for identifying breast cancers with defective DNA damage response
por: Min, Ahrum, et al.
Publicado: (2020)

Insights into the Interaction Mechanisms of the Proviral Integration Site of Moloney Murine Leukemia Virus (Pim) Kinases with Pan-Pim Inhibitors PIM447 and AZD1208: A Molecular Dynamics Simulation and MM/GBSA Calculation Study
por: Chen, Qingqing, et al.
Publicado: (2019)

PIM kinase inhibitor, AZD1208, inhibits protein translation and induces autophagy in primary chronic lymphocytic leukemia cells
por: Cervantes-Gomez, Fabiola, et al.
Publicado: (2019)

PAI1 is a Marker of Bad Prognosis in Rectal Cancer but Predicts a Better Response to Treatment with PIM Inhibitor AZD1208
por: Muñoz-Galván, Sandra, et al.
Publicado: (2020)

TDP1 and TOP1 Modulation in Olaparib-Resistant Cancer Determines the Efficacy of Subsequent Chemotherapy
por: Kim, Jin Won, et al.
Publicado: (2020)

AZD1208, a Pan-Pim Kinase Inhibitor, Has Anti-Growth Effect on 93T449 Human Liposarcoma Cells via Control of the Expression and Phosphorylation of Pim-3, mTOR, 4EBP-1, S6, STAT-3 and AMPK
por: Yadav, Anil Kumar, et al.
Publicado: (2019)

Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer
por: Luszczak, Sabina, et al.
Publicado: (2020)

Antitumor Effect of KX-01 through Inhibiting Src Family Kinases and Mitosis
por: Kim, Seongyeong, et al.
Publicado: (2017)

Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors
por: Kim, Tae Min, et al.
Publicado: (2018)

Author Correction: Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer
por: Luszczak, Sabina, et al.
Publicado: (2020)

The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells
por: Mazzacurati, Lucia, et al.
Publicado: (2015)

Genomic profile of metastatic breast cancer patient-derived xenografts established using percutaneous biopsy
por: Kim, Seongyeong, et al.
Publicado: (2021)

EGFR or HER2 inhibition modulates the tumor microenvironment by suppression of PD-L1 and cytokines release
por: Suh, Koung Jin, et al.
Publicado: (2017)

PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation
por: Min, Ahrum, et al.
Publicado: (2020)

AZD8186 in Combination With Paclitaxel in Patients With Advanced Gastric Cancer: Results From a Phase Ib/II Study (KCSG ST18-20)
por: Suh, Koung Jin, et al.
Publicado: (2023)

Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers
por: Cortes, Jorge, et al.
Publicado: (2018)

Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells
por: Min, Ahrum, et al.
Publicado: (2015)

Adenoid Cystic Carcinoma of the Breast: A Case Series of Six Patients and Literature Review
por: Kim, Miso, et al.
Publicado: (2014)

A Real-World Efficacy of Nab-Paclitaxel Monotherapy in Metastatic Breast Cancer
por: Kim, Jung Sun, et al.
Publicado: (2022)

MiR-1208 Increases the Sensitivity to Cisplatin by Targeting TBCK in Renal Cancer Cells
por: Kim, Eun-Ae, et al.
Publicado: (2019)

The HER2 S310F Mutant Can Form an Active Heterodimer with the EGFR, Which Can Be Inhibited by Cetuximab but Not by Trastuzumab as well as Pertuzumab
por: Shin, Jung Won, et al.
Publicado: (2019)

TGF-β Suppresses COX-2 Expression by Tristetraprolin-Mediated RNA Destabilization in A549 Human Lung Cancer Cells
por: Kang, Soyeong, et al.
Publicado: (2015)

Immune recurrence score using 7 immunoregulatory protein expressions can predict recurrence in stage I–III breast cancer patients
por: Lee, Dae-Won, et al.
Publicado: (2019)

BGJ398, A Pan-FGFR Inhibitor, Overcomes Paclitaxel Resistance in Urothelial Carcinoma with FGFR1 Overexpression
por: Kim, Se Hyun, et al.
Publicado: (2018)

HLA‐B27 association of autoimmune encephalitis induced by PD‐L1 inhibitor
por: Chang, Hyeyeon, et al.
Publicado: (2020)

Prognostic Role of Androgen Receptor Expression in Surgically Resected Early Breast Cancer Patients
por: Yang, Yaewon, et al.
Publicado: (2020)

Protective effects of cell permeable Tat-PIM2 protein on oxidative stress induced dopaminergic neuronal cell death
por: Shin, Min Jea, et al.
Publicado: (2023)

Mechanism of carrier controllability with metal capping layer on amorphous oxide SiZnSnO semiconductor
por: Lee, Byeong Hyeon, et al.
Publicado: (2019)

COLLABORATION AGREEMENT No. K 1208 & K 1397
por: The European Organisation for Nuclear Research, CERN, et al.
Publicado: (2005)

Korean Cancer Patients’ Awareness of Clinical Trials, Perceptions on the Benefit and Willingness to Participate
por: Lim, Yoojoo, et al.
Publicado: (2017)

CA19-9 or CEA Decline after the First Cycle of Treatment Predicts Survival in Advanced Biliary Tract Cancer Patients Treated with S-1 and Cisplatin Chemotherapy
por: Lee, Dae-Won, et al.
Publicado: (2017)

Adjuvant Chemotherapy in Microsatellite Instability–High Gastric Cancer
por: Kim, Jin Won, et al.
Publicado: (2020)

1208. Omadacycline In Vitro Activity Against Bacillus Anthracis
por: Serio, Alisa W, et al.
Publicado: (2021)

Skeletal muscle depletion predicts survival of patients with advanced biliary tract cancer undergoing palliative chemotherapy
por: Cho, Kyoung-Min, et al.
Publicado: (2017)

Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy is useful to predict a more accurate prognosis of advanced biliary tract cancer
por: Cho, Kyoung-Min, et al.
Publicado: (2016)

Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker
por: Keam, Bhumsuk, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_tqrhjra802onpem75hh4plvie9